Agents that target dyslipidaemia, such as statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, are effective in atherosclerosis stabilization and regression.283 Therapies to safely improve the material properties of the arterial wall can modify VA. Here, PCSK9 is linked to inherited lipid metabolism disorder.